Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $10,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $501 | $0 | $0 | $0 |
| Gross Profit | $9,499 | $0 | $0 | $0 |
| % Margin | 95% | – | – | – |
| R&D Expenses | $34,629 | $34,664 | $25,055 | $20,806 |
| G&A Expenses | $0 | $10,454 | $9,842 | $8,216 |
| SG&A Expenses | $10,121 | $10,454 | $9,842 | $8,216 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $44,750 | $45,118 | $34,897 | $29,022 |
| Operating Income | -$35,251 | -$45,118 | -$34,897 | -$29,022 |
| % Margin | -352.5% | – | – | – |
| Other Income/Exp. Net | $10,938 | $11,260 | $11,389 | $8,806 |
| Pre-Tax Income | -$24,313 | -$33,858 | -$23,508 | -$20,216 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24,313 | -$33,858 | -$23,508 | -$20,216 |
| % Margin | -243.1% | – | – | – |
| EPS | -0.39 | -0.55 | -0.38 | -0.36 |
| % Growth | 29.1% | -44.7% | -5.6% | – |
| EPS Diluted | -0.39 | -0.55 | -0.38 | -0.36 |
| Weighted Avg Shares Out | 62,024 | 61,902 | 61,792 | 56,832 |
| Weighted Avg Shares Out Dil | 62,024 | 61,902 | 61,792 | 56,832 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,938 | $11,260 | $11,389 | $8,806 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $501 | $541 | $519 | $512 |
| EBITDA | -$23,812 | -$44,577 | -$34,378 | -$28,510 |
| % Margin | -238.1% | – | – | – |